163 results on '"Carr, Daniel F."'
Search Results
2. Platelet-derived growth factor D expression in adrenal cells is modulated by corticosteroids: putative role in adrenal suppression
- Author
-
Parry, Christopher M., Chan, Li F., Carr, Daniel F., and Hawcutt, Daniel B.
- Published
- 2023
- Full Text
- View/download PDF
3. The association of ABCB1 gene polymorphism with clinical response to carbamazepine monotherapy in patients with epilepsy
- Author
-
Rashid, Haroon Ur, Ullah, Shakir, Carr, Daniel F., Khattak, Muhammad Ijaz Khan, Asad, Muhammad Imran, Rehman, Mujeeb Ur, and Tipu, Muhammad Khalid
- Published
- 2024
- Full Text
- View/download PDF
4. Transcobalamin receptor gene polymorphisms and mutation in an elderly population
- Author
-
McCaddon, Andrew, Carr, Daniel F., Peter, Hudson, Moat, Stuart J., and Quadros, Edward V.
- Published
- 2023
- Full Text
- View/download PDF
5. Pharmacogenomics of Anti-Cancer Drugs
- Author
-
Carr, Daniel F., primary, Turner, Richard M., additional, and Pirmohamed, Munir, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Precision medicine in drug safety
- Author
-
Carr, Daniel F. and Pirmohamed, Munir
- Published
- 2020
- Full Text
- View/download PDF
7. Urticarial Reactions to Drugs
- Author
-
Carr, Daniel F., Shear, Neil H., editor, and Dodiuk-Gad, Roni P., editor
- Published
- 2019
- Full Text
- View/download PDF
8. A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis
- Author
-
Foulkes, Amy C., Watson, David S., Carr, Daniel F., Kenny, John G., Slidel, Timothy, Parslew, Richard, Pirmohamed, Munir, Anders, Simon, Reynolds, Nick J., Griffiths, Christopher E.M., Warren, Richard B., and Barnes, Michael R.
- Published
- 2019
- Full Text
- View/download PDF
9. Corrigendum: CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study
- Author
-
McEvoy, Laurence, primary, Cliff, Joanne, additional, Carr, Daniel F, additional, Jorgensen, Andrea, additional, Lord, Rosemary, additional, and Pirmohamed, Munir, additional
- Published
- 2023
- Full Text
- View/download PDF
10. CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study
- Author
-
McEvoy, Laurence, primary, Cliff, Joanne, additional, Carr, Daniel F, additional, Jorgensen, Andrea, additional, Lord, Rosemary, additional, and Pirmohamed, Munir, additional
- Published
- 2023
- Full Text
- View/download PDF
11. TNF‐α induced extracellular release of keratinocyte high‐mobility group box 1 in Stevens‐Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesis
- Author
-
Nwikue, Gospel, primary, Olsson‐Brown, Anna, additional, Aboheimed, Nourah, additional, Yip, Vincent, additional, Jolly, Carol, additional, Luchian, Andreea, additional, Ressel, Lorenzo, additional, Sharma, Anurag, additional, Bergfeld, Wilma, additional, Ahmed, Shaheda, additional, Dickinson, Anne, additional, Pirmohamed, Munir, additional, and Carr, Daniel F., additional
- Published
- 2023
- Full Text
- View/download PDF
12. TNF-α‒Mediated Keratinocyte Expression and Release of Matrix Metalloproteinase 9: Putative Mechanism of Pathogenesis in Stevens‒Johnson Syndrome/Toxic Epidermal Necrolysis
- Author
-
Olsson-Brown, Anna, primary, Yip, Vincent, additional, Ogiji, Emeka D., additional, Jolly, Carol, additional, Ressel, Lorenzo, additional, Sharma, Anurag, additional, Bergfeld, Wilma, additional, Liu, Xuan, additional, Khirwadkar, Nitin, additional, Bellon, Teresa, additional, Dickinson, Anne, additional, Ahmed, Shaheda, additional, Langton, Abigail, additional, Watson, Rachel, additional, Pirmohamed, Munir, additional, and Carr, Daniel F., additional
- Published
- 2023
- Full Text
- View/download PDF
13. Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study
- Author
-
Hawcutt, Daniel B, Francis, Ben, Carr, Daniel F, Jorgensen, Andrea L, Yin, Peng, Wallin, Naomi, O'Hara, Natalie, Zhang, Eunice J, Bloch, Katarzyna M, Ganguli, Amitava, Thompson, Ben, McEvoy, Laurence, Peak, Matthew, Crawford, Andrew A, Walker, Brian R, Blair, Joanne C, Couriel, Jonathan, Smyth, Rosalind L, and Pirmohamed, Munir
- Published
- 2018
- Full Text
- View/download PDF
14. Urticarial Reactions to Drugs
- Author
-
Carr, Daniel F., primary
- Published
- 2018
- Full Text
- View/download PDF
15. CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia
- Author
-
Johnson, Gillian G., Lin, Ke, Cox, Trevor F., Oates, Melanie, Sibson, David R., Eccles, Richard, Lloyd, Bryony, Gardiner, Laura-Jayne, Carr, Daniel F., Pirmohamed, Munir, Strefford, Jonathan C., Oscier, David G., Gonzalez de Castro, David, Else, Monica, Catovsky, Daniel, and Pettitt, Andrew R.
- Published
- 2013
- Full Text
- View/download PDF
16. Advances in the Pharmacogenomics of Adverse Drug Reactions
- Author
-
Collins, Susannah L., Carr, Daniel F., and Pirmohamed, Munir
- Published
- 2016
- Full Text
- View/download PDF
17. Platelet-derived growth factor D expression in adrenal cells is modulated by corticosteroids: putative role in adrenal suppression
- Author
-
Parry, Christopher M., primary, Chan, Li F., additional, Carr, Daniel F., additional, and Hawcutt, Daniel B., additional
- Published
- 2022
- Full Text
- View/download PDF
18. Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population
- Author
-
Carr, Daniel F., Chaponda, Mas, Jorgensen, Andrea L., Castro, Elena Cornejo, van Oosterhout, Joep J., Khoo, Saye H., Lalloo, David G., Heyderman, Robert S., Alfirevic, Ana, and Pirmohamed, Munir
- Published
- 2013
- Full Text
- View/download PDF
19. Beclometasone but not fluticasone modulates PDGFD expression in the H295R adrenal cell line.
- Author
-
Parry, Christopher M, primary, Chan, Li F, additional, Carr, Daniel F, additional, and Hawcutt, Daniel B, additional
- Published
- 2021
- Full Text
- View/download PDF
20. Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration
- Author
-
Bourgeois, Stephane, primary, Carr, Daniel F., additional, Musumba, Crispin O., additional, Penrose, Alexander, additional, Esume, Celestine, additional, Morris, Andrew P., additional, Jorgensen, Andrea L., additional, Zhang, J. Eunice, additional, Pritchard, D. Mark, additional, Deloukas, Panos, additional, and Pirmohamed, Munir, additional
- Published
- 2021
- Full Text
- View/download PDF
21. CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations
- Author
-
Carr, Daniel F., Chaponda, Mas, Cornejo Castro, Elena M., Jorgensen, Andrea L., Khoo, Saye, Van Oosterhout, Joep J., Dandara, Collet, Kampira, Elizabeth, Ssali, Francis, Munderi, Paula, Lalloo, David G., Heyderman, Robert S., and Pirmohamed, Munir
- Published
- 2014
- Full Text
- View/download PDF
22. Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment
- Author
-
van Staa, Tjeerd P., Carr, Daniel F., OʼMeara, Helen, McCann, Gerry, and Pirmohamed, Munir
- Published
- 2014
- Full Text
- View/download PDF
23. Beta-lactam-induced immediate hypersensitivity reactions: A genome-wide association study of a deeply phenotyped cohort
- Author
-
Nicoletti, Paola, primary, Carr, Daniel F., additional, Barrett, Sarah, additional, McEvoy, Laurence, additional, Friedmann, Peter S., additional, Shear, Neil H., additional, Nelson, Matthew R., additional, Chiriac, Anca M., additional, Blanca-López, Natalia, additional, Cornejo-García, José A., additional, Gaeta, Francesco, additional, Nakonechna, Alla, additional, Torres, Maria J., additional, Caruso, Cristiano, additional, Valluzzi, Rocco L., additional, Floratos, Aris, additional, Shen, Yufeng, additional, Pavlos, Rebecca K., additional, Phillips, Elizabeth J., additional, Demoly, Pascal, additional, Romano, Antonino, additional, Blanca, Miguel, additional, and Pirmohamed, Munir, additional
- Published
- 2021
- Full Text
- View/download PDF
24. Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?
- Author
-
Johnson, Gillian G, Carr, Daniel F, Pirmohamed, Munir, and Pettitt, Andrew R
- Published
- 2014
- Full Text
- View/download PDF
25. Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink
- Author
-
OʼMeara, Helen, Carr, Daniel F., Evely, Jane, Hobbs, Mark, McCann, Gerard, van Staa, Tjeerd, and Pirmohamed, Munir
- Published
- 2014
- Full Text
- View/download PDF
26. Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine
- Author
-
Yip, Vincent L.M., primary, Pertinez, Henry, additional, Meng, Xiaoli, additional, Maggs, James L., additional, Carr, Daniel F., additional, Park, B. Kevin, additional, Marson, Anthony G., additional, and Pirmohamed, Munir, additional
- Published
- 2020
- Full Text
- View/download PDF
27. Institutional Profile: The Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UK
- Author
-
Alfirevic, Ana, Carr, Daniel F, Miyajima, Fabio, Pushpakom, Sudeep, Sutton, Laura, Jorgensen, Andrea L, and Pirmohamed, Munir
- Published
- 2013
- Full Text
- View/download PDF
28. Conference Scene: Report on the 8th Annual Cold Spring Harbor/Wellcome Trust meeting on Pharmacogenomics and Personalized Medicine
- Author
-
Carr, Daniel F and Alfirevic, Ana
- Published
- 2011
- Full Text
- View/download PDF
29. Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response
- Author
-
Carr, Daniel F., primary, Turner, Richard M., additional, and Pirmohamed, Munir, additional
- Published
- 2020
- Full Text
- View/download PDF
30. Informatics investigations into anti-thyroid drug induced agranulocytosis associated with multiple HLA-B alleles
- Author
-
Ramsbottom, Kerry A., primary, Carr, Daniel F., additional, Rigden, Daniel J., additional, and Jones, Andrew R., additional
- Published
- 2020
- Full Text
- View/download PDF
31. Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics
- Author
-
Elliot, Emilie R, primary, Neary, Megan, primary, Else, Laura, primary, Khoo, Saye, primary, Moyle, Graeme, primary, Carr, Daniel F, primary, Wang, Xinzhu, primary, Mcclure, Myra, primary, Boffito, Marta, primary, and Owen, Andrew, primary
- Published
- 2020
- Full Text
- View/download PDF
32. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort
- Author
-
Carr, Daniel F., la Porte, Charles J., Pirmohamed, Munir, Owen, Andrew, and Cortes, Claudia P.
- Published
- 2010
- Full Text
- View/download PDF
33. Pharmacogenomics of statin-related myopathy : Meta-analysis of rare variants from whole-exome sequencing
- Author
-
Floyd, James S., Bloch, Katarzyna M., Brody, Jennifer A., Maroteau, Cyrielle, Siddiqui, Moneeza K., Gregory, Richard, Carr, Daniel F., Molokhia, Mariam, Liu, Xiaoming, Bis, Joshua C., Ahmed, Ammar, Liu, Xuan, Hallberg, Pär, Yue, Qun-Ying, Magnusson, Patrik K. E., Brisson, Diane, Wiggins, Kerri L., Morrison, Alanna C., Khoury, Etienne, McKeigue, Paul, Stricker, Bruno H., Lapeyre-Mestre, Maryse, Heckbert, Susan R., Gallagher, Arlene M., Chinoy, Hector, Gibbs, Richard A., Bondon-Guitton, Emmanuelle, Tracy, Russell, Boerwinkle, Eric, Gaudet, Daniel, Conforti, Anita, van Staa, Tjeerd, Sitlani, Colleen M., Rice, Kenneth M., Maitland-van der Zee, Anke-Hilse, Wadelius, Mia, Morris, Andrew P., Pirmohamed, Munir, Palmer, Colin A. N., Psaty, Bruce M., Alfirevic, Ana, Baranova, Ekaterina V., Eriksson, Niclas, Aaspollu, Anu, McCarthy, Alun, Delrieu, Olivier, Paediatric Pulmonology, Pulmonology, and APH - Personalized Medicine
- Subjects
0301 basic medicine ,Critical Care and Emergency Medicine ,Genome-wide association study ,Pathology and Laboratory Medicine ,Bioinformatics ,Rhabdomyolysis ,Mathematical and Statistical Techniques ,0302 clinical medicine ,Medicine and Health Sciences ,Drug Interactions ,Trauma Medicine ,Exome sequencing ,Multidisciplinary ,Statistics ,Drugs ,High-Throughput Nucleotide Sequencing ,Metaanalysis ,3. Good health ,Research Design ,030220 oncology & carcinogenesis ,Physical Sciences ,Engineering and Technology ,Medicine ,medicine.symptom ,Traumatic Injury ,Medical Genetics ,Research Article ,Quality Control ,GENETIC VARIANT, Muscular Diseases, Pharmacokinetics, Statin-induced myopathy ,Science ,GENETIC VARIANT ,Drug-Drug Interactions ,Research and Analysis Methods ,03 medical and health sciences ,Signs and Symptoms ,Adverse Reactions ,Muscular Diseases ,Diagnostic Medicine ,Industrial Engineering ,medicine ,Humans ,Pharmacokinetics ,Statistical Methods ,Muscle, Skeletal ,Myopathy ,Genetic association ,Medicinsk genetik ,Pharmacology ,Whole Genome Sequencing ,business.industry ,Statins ,Case-control study ,medicine.disease ,Minor allele frequency ,030104 developmental biology ,Case-Control Studies ,Musculoskeletal Injury ,Pharmacogenomics ,Statin-induced myopathy ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business ,Mathematics ,Adverse drug reaction ,Genome-Wide Association Study - Abstract
AIMS: Statin-related myopathy (SRM), which includes rhabdomyolysis, is an uncommon but important adverse drug reaction because the number of people prescribed statins world-wide is large. Previous association studies of common genetic variants have had limited success in identifying a genetic basis for this adverse drug reaction. We conducted a multi-site whole-exome sequencing study to investigate whether rare coding variants confer an increased risk of SRM.METHODS AND RESULTS: SRM 3-5 cases (N = 505) and statin treatment-tolerant controls (N = 2047) were recruited from multiple sites in North America and Europe. SRM 3-5 was defined as symptoms consistent with muscle injury and an elevated creatine phosphokinase level >4 times upper limit of normal without another likely cause of muscle injury. Whole-exome sequencing and variant calling was coordinated from two analysis centres, and results of single-variant and gene-based burden tests were meta-analysed. No genome-wide significant associations were identified. Given the large number of cases, we had 80% power to identify a variant with minor allele frequency of 0.01 that increases the risk of SRM 6-fold at genome-wide significance.CONCLUSIONS: In this large whole-exome sequencing study of severe statin-related muscle injury conducted to date, we did not find evidence that rare coding variants are responsible for this adverse drug reaction. Larger sample sizes would be required to identify rare variants with small effects, but it is unclear whether such findings would be clinically actionable.
- Published
- 2019
34. Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine.
- Author
-
Yip, Vincent L.M., Pertinez, Henry, Meng, Xiaoli, Maggs, James L., Carr, Daniel F., Park, B. Kevin, Marson, Anthony G., and Pirmohamed, Munir
- Subjects
PHARMACOKINETICS ,CARBAMAZEPINE ,SINGLE nucleotide polymorphisms ,GENETIC variation ,EPOXIDE hydrolase ,DRUG dosage - Abstract
Aims: Carbamazepine can cause hypersensitivity reactions in ~10% of patients. An immunogenic effect can be produced by the electrophilic 10,11‐epoxide metabolite but not by carbamazepine. Hypothetically, certain single nucleotide polymorphisms might increase the formation of immunogenic metabolites, leading ultimately to hypersensitivity reactions. This study explores the role of clinical and genetic factors in the pharmacokinetics (PK) of carbamazepine and 3 metabolites known to be chemically reactive or formed through reactive intermediates. Methods: A combination of rich and sparse PK samples were collected from healthy volunteers and epilepsy patients. All subjects were genotyped for 20 single nucleotide polymorphisms in 11 genes known to be involved in the metabolism or transport of carbamazepine and carbamazepine 10,11‐epoxide. Nonlinear mixed effects modelling was used to build a population‐PK model. Results: In total, 248 observations were collected from 80 subjects. A 1‐compartment PK model with first‐order absorption and elimination best described the parent carbamazepine data, with a total clearance of 1.96 L/h, central distribution volume of 164 L and absorption rate constant of 0.45 h−1. Total daily dose and coadministration of phenytoin were significant covariates for total clearance of carbamazepine. EPHX1‐416G/G genotype was a significant covariate for the clearance of carbamazepine 10,11‐epoxide. Conclusion: Our data indicate that carbamazepine clearance was affected by total dose and phenytoin coadministration, but not by genetic factors, while carbamazepine 10,11‐epoxide clearance was affected by a variant in the microsomal epoxide hydrolase gene. A much larger sample size would be required to fully evaluate the role of genetic variation in carbamazepine pharmacokinetics, and thereby predisposition to carbamazepine hypersensitivity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. Genomewide Association Study of Statin‐Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink
- Author
-
Carr, Daniel F., primary, Francis, Ben, additional, Jorgensen, Andrea L., additional, Zhang, Eunice, additional, Chinoy, Hector, additional, Heckbert, Susan R., additional, Bis, Joshua C., additional, Brody, Jennifer A., additional, Floyd, James S., additional, Psaty, Bruce M., additional, Molokhia, Mariam, additional, Lapeyre‐Mestre, Maryse, additional, Conforti, Anita, additional, Alfirevic, Ana, additional, Staa, Tjeerd, additional, and Pirmohamed, Munir, additional
- Published
- 2019
- Full Text
- View/download PDF
36. Informatics investigations into anti-thyroid drug induced agranulocytosis associated with multiple HLA-B alleles
- Author
-
Ramsbottom, Kerry A, primary, Carr, Daniel F, additional, Rigden, Daniel J, additional, and Jones, Andrew R, additional
- Published
- 2019
- Full Text
- View/download PDF
37. Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study
- Author
-
Hope, William, primary, Johnstone, Gary, additional, Cicconi, Silvia, additional, Felton, Timothy, additional, Goodwin, Joanne, additional, Whalley, Sarah, additional, Santoyo-Castelazo, Anahi, additional, Ramos-Martin, Virginia, additional, Lestner, Jodi, additional, Credidio, Leah, additional, Dane, Aaron, additional, Carr, Daniel F., additional, Pirmohamed, Munir, additional, Salim, Rahim, additional, and Neely, Michael, additional
- Published
- 2019
- Full Text
- View/download PDF
38. Critical assessment of approaches for molecular docking to elucidate associations of HLA alleles with adverse drug reactions
- Author
-
Ramsbottom, Kerry A., primary, Carr, Daniel F., additional, Jones, Andrew R., additional, and Rigden, Daniel J., additional
- Published
- 2018
- Full Text
- View/download PDF
39. Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response.
- Author
-
Carr, Daniel F., Turner, Richard M., and Pirmohamed, Munir
- Subjects
- *
ANTINEOPLASTIC agents , *PHARMACOGENOMICS , *DRUG therapy , *MYELOSUPPRESSION , *DRUG efficacy , *GENES - Abstract
The field of pharmacogenomics has made great strides in oncology over the last 20 years and indeed a significant number of pre‐emptive genetic tests are now routinely undertaken prior to anticancer drug administration. Many of these gene–drug interactions are the fruits of candidate gene and genome‐wide association studies, which have largely focused on common genetic variants (allele frequency>1%). Examples where there is clinical utility include genotyping or phenotyping for G6PD to prevent rasburicase‐induced RBC haemolysis, and TPMT to prevent thiopurine‐induced bone marrow suppression. Other associations such as CYP2D6 status in determining the efficacy of tamoxifen are more controversial because of contradictory evidence from different sources, which has led to variability in the implementation of testing. As genomic technology becomes ever cheaper and more accessible, we must look to the additional data our genome can provide to explain interindividual variability in anticancer drug response. Clearly genes do not act on their own and it is therefore important to investigate genetic factors in conjunction with clinical factors, interacting concomitant drug therapies and other factors such as the microbiome, which can all affect drug disposition. Taking account of all of these factors, in conjunction with the somatic genome, is more likely to provide better predictive accuracy in determining anticancer drug response, both efficacy and safety. This review summarises the existing knowledge related to the pharmacogenomics of anticancer drugs and discusses areas of opportunity for further advances in personalisation of therapy in order to improve both drug safety and efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. Biomarkers of adverse drug reactions
- Author
-
Carr, Daniel F, primary and Pirmohamed, Munir, additional
- Published
- 2017
- Full Text
- View/download PDF
41. Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G -> T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis
- Author
-
Nightingale, Sam, Chau, Tran Thi Hong, Fisher, Martin, Nelson, Mark, Winston, Alan, Else, Laura, Carr, Daniel F, Taylor, Steven, Ustianowski, Andrew, Back, David, Pirmohamed, Munir, Solomon, Tom, Farrar, Jeremy, Toerok, M Estee, Khoo, Saye, and Grp, PARTITION-Vietnam Study
- Abstract
Efavirenz (EFZ) has been associated with neuropsychiatric side effects. Recently, the 8-hydroxy-EFZ (8OH-EFZ) metabolite has been shown to be a potent neurotoxin in vitro, inducing neuronal damage at concentrations of 3.3 ng/ml. EFZ induced similar neuronal damage at concentrations of 31.6 ng/ml. We investigated the effect of genotype and blood-brain barrier integrity on EFZ metabolite concentrations in cerebrospinal fluid (CSF). We measured CSF drug concentrations in subjects from two separate study populations: 47 subjects with tuberculous meningitis (TBM) coinfection in Vietnam receiving 800 mg EFZ with standard antituberculous treatment and 25 subjects from the PARTITION study in the United Kingdom without central nervous system infection receiving 600 mg EFZ. EFZ and metabolite concentrations in CSF and plasma were measured and compared with estimates of effectiveness and neurotoxicity from available published in vitro and in vivo data. The effect of the CYP2B6 c.516G→T genotype (GG genotype, fast EFV metabolizer status; GT genotype, intermediate EFV metabolizer status; TT genotype, slow EFV metabolizer status) was examined. The mean CSF concentrations of EFZ and 8OH-EFZ in the TBM group were 60.3 and 39.3 ng/ml, respectively, and those in the no-TBM group were 15.0 and 5.9 ng/ml, respectively. Plasma EFZ and 8OH-EFZ concentrations were similar between the two groups. CSF EFZ concentrations were above the in vitro toxic concentration in 76% of samples (GG genotype, 61%; GT genotype, 90%; TT genotype, 100%) in the TBM group and 13% of samples (GG genotype, 0%; GT genotype, 18%; TT genotype, 50%) in the no-TBM group. CSF 8OH-EFZ concentrations were above the in vitro toxic concentration in 98% of the TBM group and 87% of the no-TBM group; levels were independent of genotype but correlated with the CSF/plasma albumin ratio. Potentially neurotoxic concentrations of 8OH-EFZ are frequently observed in CSF independently of the CYP2B6 genotype, particularly in those with impaired blood-brain barrier integrity.
- Published
- 2016
42. 7th drug hypersensitivity meeting: part one
- Author
-
Carr, Daniel F., Chung, Wen-Hung, Jenkiins, Rosalind E., Chaponda, Mas, Nwikue, Gospel, Cornejo Castro, Elena M., Antoine, Daniel J., Pirmohamed, Munir, Wuillemin, Natascha, Dina, Dolores, Eriksson, Klara K., Yerly, Daniel, Pavlos, Rebecca, Mckinnin, Elizabeth, Ostrov, David, Peters, Bjoern, Buus, Soren, Koelle, David, Chopra, Abha, Rive, Craig, Redwood, Alec, Restrepo, Susana, Bracey, Austin, Yuan, Jing, Gaudieri, Silvana, Carrington, Mary, Haas, David, Mallal, Simon, Phillips, Elizabeth, De Boer, Douwe, Menheere, Paul, Nieuwhof, Chris, Bons, Judith, Jonsson, Friederike, De Chaisemartin, Luc, Granger, Vanessa, Gillis, Caitlin, Gouel, Aurelie, Neukirch, Catherine, Dib, Fadia, Nicaise, Pascale Roland, Longrois, Dan, Tubach, Florence, Martin, Sylvie, Bruhns, Pierre, Chen, Kai-Lung, Liao, Shu-Ling, Sheen, Yi-Shuan, Cho, Yung-Tsu, Yang, Che-Wen, Liau, Jau-Yu, Chu, Chia-Yu, Aguiar, Rita, Lopes, Anabela, Fernandes, Natália, Viegas, Leonor, Pereira-Barbosa, M. A., Bünter, Antonia, Gupta, Nisha, Petkovic, Tatjana Pecaric, Wirth, Nicole, Pichler, Werner J., Hausmann, Oliver, Yazicioglu, Mehtap, Ozdemir, Pinar G., Ciplak, Gokce, Kaya, Ozkan, Cooke, Peter John, Mota, Inês, Gaspar, Ângela, Benito-Garcia, Filipe, Chambel, Marta, Morais-Almeida, Mário, Marques, Luis, Alcoceba, Eva, Lara, Silvia, Carneiro-Leão, Leonor, Botelho, Carmen, Dias-Castro, Eunice, Cernadas, Josefina R., Nicholls, Katherine, Lay, William, Smith, Olivia, Collins, Christine, Unglik, Gary, Spriggs, Kymble, Auyeung, Priscilla, McComish, Jeremy, Douglass, Jo A., Peter, Jonny G., Potter, Paul, Carolino, Fabrícia, De Castro, Eunice Dias, Moreira, Ana Sofia, Abreu, Carmo, Gomes, Eva, Cardoso, Bárbara Kong, Tomaz, Elza, Correia, Sara, Inácio, Filipe, Arnold, Annabelle, Bear, Natasha, Rueter, Kristina, Gong, Grace, O’Sullivan, Michael, Muthusamy, Saravanan, Noble, Valerie, Lucas, Michaela, Buterleviciute, Neringa, Rudzeviciene, Odilija, May, Sara, Pongdee, Thanai, Park, Miguel, Griguola, Linas, Vinikovas, Arturas, Kašinskaite, Simona, Kvedariene, Violeta, Aktas, Ayse, Rahman, Suheyla, Elbi, Huseyin, Ozyurt, Beyhan Cengiz, Cavkaytar, Ozlem, Karaatmaca, Betul, Cetinkaya, Pinar Gur, Esenboga, Saliha, Sahiner, Umit M., Sekerel, Bulent E., Soyer, Ozge, Zubrinich, Celia, Tong, Bianca, Patel, Mittal, Giles, Michelle, O’Hehir, Robyn, Puy, Robert, Amaral, Luís, Demir, Semra, Gelincik, Asli, Olgac, Muge, Caskun, Raif, Unal, Derya, Colakoglu, Bahauddin, Buyukozturk, Suna, Matute, Olga Vega, Bernad, Amalia, Gastaminza, Gabriel, Madamba, Roselle, Lacasa, Carlos, Goikoetxea, M. J., D’Amelio, Carmen, Rifón, Jose, Martínez, Nicolas, Ferrer, Marta, Ribeiro, Carmelita, Faria, Emília, Frutuoso, Cristina, Barros, Anabela, Lebre, Rosário, Pego, Alice, Bom, Ana Todo, Ensina, Luis Felipe, Aranda, Carolina, Nunes, Ines Camelo, Martins, Ana Maria, Solé, Dirceu, Bavbek, Sevim, Kendirlinan, Resat, Çerçi, Pamir, Tutluer, Seda, Soyyigit, Sadan, Sözener, Zeynep Çelebi, Aydin, Ömür, Gümüsburun, Reyhan, Almeida, Marta, Sai, Kimie, Imatoh, Takuya, Nakamura, Ryosuke, Fukazawa, Chisato, Hinomura, Yasushi, Saito, Yoshiro, Sousa-Pinto, Bernardo, Correia, Cláudia, Gomes, Lídia, Gil-Mata, Sara, Araújo, Luís, Delgado, Luís, Okamoto-Uchida, Yoshimi, Kajinami, Koji, Matsunaga, Kayoko, Aihara, Michiko, Wang, Chuang-Wei, Su, Shih-Chi, Hung, Shuen-Iu, Ho, Hsin-Chun, Yang, Chih-Hsun, Paulmann, Maren, Dunant, Ariane, Mockenhaupt, Maja, Sekula, Peggy, Schumacher, Martin, Kardaun, Sylvia, Naldi, Luigi, Bellón, Teresa, Creamer, Daniel, Haddad, Cynthia, Sassolas, Bruno, Lebrun-Vignes, Bénédicte, Valeyrie-Allanore, Laurence, Roujeau, Jean-Claude, Kremmler, Carmen, Dodiuk-Gad, Roni P., Olteanu, Cristina, Feinstein, Anthony, Hashimoto, Rena, Alhusayen, Raed, Whyte-Croasdaile, Sonia, Finkelstein, Yaron, Burnett, Marjorie, Sade, Shachar, Cartotto, Robert, Jeschke, Marc, Shear, Neil H., Takamura, Naoko, Yamane, Yumiko, Matsukura, Setsuko, Nakamura, Kazuko, Watanabe, Yuko, Yamaguchi, Yukie, Kambara, Takeshi, Ikezawa, Zenro, Chew, Hall, Knezevic, Brittany, Ionmhain, Una Nic, Barraclough, Allison, Anstey, Matthew, Usui, Toru, Meng, Xiaoli, Farrell, John, Whitaker, Paul, Watson, John, French, Neil, Park, Kevin, Naisbitt, Dean, Neves, Ana Castro, Cadinha, Susana, Moreira, Ana, Da Silva, J. P. Moreira, Drvar, Daniela Ledic, Gulin, Sandra Jerkovic, Hadzavdic, Suzana Ljubojevic, Ceovic, Romana, De Francisco, Ana Montoro, De Vicente Jiménez, Talía, Luque, Amelia García, David, Natalia Rosado, Galván, José Mª Mateos, Darlenski, Razvigor, Gulin, Dario, Sikic, Jozica, Habek, Jasna Cerkez, Galic, Edvard, Specht, Philip, Staab, Doris, Mayer, Beate, Roehmel, Jobst, Solovan, Caius, Chiriac, Anca, Djurinec, Paola, Kostovic, Kresimir, Bradamante, Mirna, Almeida, Jose Pedro, Caiado, Joana, Pedro, Elisa, Da Silva, Pedro Canas, Barbosa, Manuel Pereira, Bogas, Gador, Blanca-López, Natalia, Pérez-Alzate, Diana, Doña, Inmaculada, Agúndez, José Augusto, García-Martín, Elena, Cornejo-García, José Antonio, Mayorga, Cristobalina, Torres, María José, Canto, Maria Gabriela, Blanca, Miguel, Aksakal, Sengül, Sin, Aytül Zerrin, Koç, Zeynep Peker, Günsen, Fatma Düsünür, Ardeniz, Ömür, Gökmen, Emine Nihal Mete, Gülbahar, Okan, Kokuludag, Ali, Pérez-Sánchez, Natalia, Salas, María, Salas, Maria, Gomez, Francisca, Barrionuevo, Esther, Andreu, Inmaculada, Miranda, Miguel Ángel, Didžiokaite, Gabija, Gaidej, Olesia, Garcimartin, Maria Isabel, Somoza, Maria Luisa, Bojas, Gador, Cornejo-Garcia, Jose Antonio, Perez, Francisco Javier Ruano, Miranda, Miguel Angel, Jerschow, Elina, Pelletier, Teresa, Ren, Zhen, Hudes, Golda, Sanak, Marek, Morales, Esperanza, Schuster, Victor, Spivack, Simon D, Rosenstreich, David, Erzen, Renato, Silar, Mira, Bajrovic, Nissera, Rijavec, Matija, Zidarn, Mihaela, Korosec, Peter, Castro, Eunice, Al-Ahmad, Mona, Rodriguez, Tito, Azevedo, João Pedro, Tavares, Beatriz, Regateiro, Frederico, Todo-Bom, Ana, Miranda, Pablo Andrés, De La Cruz Hoyos, Bautista, Abuzeid, Waleed, Akbar, Nadeem, Gibber, Marc, Fried, Marvin, Han, Weiguo, Keskin, Taha, Tamayev, Robert, Spivack, Simon D., Boni, Elisa, Russello, Marina, Mauro, Marina, Neto, Marta Ferreira, Brosseron, Lise, Malheiro, Daniela, Barreira, Patrícia, Sprigg, Dustin, Trevenen, Michelle, Seet, Jason, Trubiano, Jason, Smith, William, Jeelall, Yogesh, Vale, Sandra, Loh, Richard, Mclean-Tooke, Andrew, Müller, Sabine, Amstutz, Ursula, Jörg, Lukas, Yawalkar, Nikhil, Krähenbühl, Stephan, Leblanc, Ana, Ribeiro, Laura, Vega, Arantza, Rivas, Raquel Gutierrez, Alonso, Ana, Beitia, Juan Maria, Mateo, Belén, Cárdenas, Remedios, Garcia-Dominguez, Juan Jesus, Strautins, Kaija, James, Ian, Neves, Ana, Do Céu Machado, Maria, Dalgiç, Ceyda Tunakan, Bulut, Gökten, Ardeniz, Fatma Ömür, Hsu, Shao-Hsuan, Ye, Young-Min, Hur, Gyu-Young, Park, Hae-Sim, Kim, Seung-Hyun, Ali, Syed, Hollingsworth, Peter N., Mclean-Tooke, Andrew P. C., Chadly, Zohra, Fredj, Nadia Ben, Aouam, Karim, Romdhane, Haifa Ben, Boughattas, Naceur A., Chaabane, Amel, Salazar, Marina Lluncor, Pola, Beatriz, Fiandor, Ana, Ramírez, Elena, Ortega, Javier Domínguez, Quirce, Santiago, Cabañas, Rosario, Baynova, Krasimira, Labella, Marina, Prados, Manuel, Ramonaite, Agne, Bajoriuniene, Ieva, Sitkauskiene, Brigita, Sakalauskas, Raimundas, Kwon, Jae-Woo, Park, Shinyoung, Silva, Diana, Leão, Leonor Carneiro, Garcimartin, Maria, De La Torre, Maria Vazquez, Pérez, Francisco Javier Ruano, Haroun, Elisa, Diez, Gabriela Canto, Ónodi-Nagy, Katinka, Kinyó, Ágnes, Kemény, Lajos, Bata-Csörgo, Zsuzsanna, Pita, Joana Sofia, Fernandes, Rosa Anita, Moura, Ana, Sousa, Nuno, Loureiro, Carlos, Pfützner, Wolfgang, Marrouche, Nadine, Grattan, Clive, Chen, Yu-En, Chen, Chun-Bing, Hsiao, Yu-Ping, and Ruano, Francisco Javier
- Subjects
Pulmonary and Respiratory Medicine ,Drug ,Allergy ,business.industry ,media_common.quotation_subject ,Immunology ,medicine.disease ,Meeting Abstracts ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Drug Hypersensitivity Syndrome ,030220 oncology & carcinogenesis ,Immunology and Allergy ,Medicine ,business ,media_common - Abstract
Table of contents Oral Abstracts O1 Functionally distinct HMGB1 isoforms correlate with physiological processes in drug-induced SJS/TEN Daniel F. Carr, Wen-Hung Chung, Rosalind E. Jenkiins, Mas Chaponda, Gospel Nwikue, Elena M. Cornejo Castro, Daniel J. Antoine, Munir Pirmohamed O2 Hypersensitivity reactions to beta-lactams, does the t cell recognition pattern influence the clinical picture? Natascha Wuillemin, Dolores Dina, Klara K. Eriksson, Daniel Yerly O3 Specific binding characteristics of HLA alleles associated with nevirapine hypersensitivity Rebecca Pavlos, Elizabeth Mckinnin, David Ostrov, Bjoern Peters, Soren Buus, David Koelle, Abha Chopra, Craig Rive, Alec Redwood, Susana Restrepo, Austin Bracey, Jing Yuan, Silvana Gaudieri, Mary Carrington, David Haas, Simon Mallal, Elizabeth Phillips O4 Do we need to measure total ige for the interpretation of analytical results of ImmunoCAP dnd 3gAllergy specific IgE? Douwe De Boer, Paul Menheere, Chris Nieuwhof, Judith Bons O5 Neutrophil activation in systemic anaphylaxis: results from the multicentric NASA study Friederike Jonsson, Luc De Chaisemartin, Vanessa Granger, Caitlin Gillis, Aurelie Gouel, Catherine Neukirch, Fadia Dib, Pascale Roland Nicaise, Dan Longrois, Florence Tubach, Sylvie Martin, Pierre Bruhns, NASA Study Group O6 Purpuric drug eruptions due to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small-cell lung cancer (NSCLC): a clinic-pathological study of 32 cases Kai-Lung Chen, Shu-Ling Liao, Yi-Shuan Sheen, Yung-Tsu Cho, Che-Wen Yang, Jau-Yu Liau, Chia-Yu Chu Poster presentations: Poster Walk 1—Anaphylaxis (P01–P09) P1 Anaphylactic reactions during anaesthesia and the perioperative period Rita Aguiar, Anabela Lopes, Natália Fernandes, Leonor Viegas, M. A. Pereira-Barbosa P2 Anaphylaxis to chlorhexidine: is there a cross-reactivity to alexidine? Antonia Bünter, Nisha Gupta, Tatjana Pecaric Petkovic, Nicole Wirth, Werner J. Pichler, Oliver Hausmann P3 Cefotaxime-induced severe anaphylaxis in a neonate Mehtap Yazicioglu, Pinar G. Ozdemir, Gokce Ciplak, Ozkan Kaya P4 Clinical features and diagnosis of anaphylaxis resulting from exposure to chlorhexidine Peter John Cooke P5 Drug-induced anaphylaxis: five-year single-center survey Inês Mota, Ângela Gaspar, Filipe Benito-Garcia, Marta Chambel, Mário Morais-Almeida P6 Intraoperative severe anaphylactic reaction due to patent blue v dye Luis Marques, Eva Alcoceba, Silvia Lara P7 Kounis syndrome in the setting of anaphylaxis to diclofenac Leonor Carneiro-Leão, Carmen Botelho, Eunice Dias-Castro, Josefina Cernadas P8 Perioperative anaphylaxis audit: Royal Melbourne Hospital Katherine Nicholls, William Lay, Olivia Smith, Christine Collins, Gary Unglik, Kymble Spriggs, Priscilla Auyeung, Jeremy McComish, Jo A. Douglass P9 Recurrent peri-operative anaphylaxis: a perfect storm Jonny G. Peter, Paul Potter Poster Walk 2: DH regions and patient groups (P10–P19) P10 A rare presentation of amoxicillin allergy in a young child Fabrícia Carolino, Eunice Dias De Castro, Josefina R. Cernadas P11 Adverse drug reactions in children: antibiotics or virus? Ana Sofia Moreira, Carmo Abreu, Eva Gomes P12 Allergic reactions in invasive medical procedures Bárbara Kong Cardoso, Elza Tomaz, Sara Correia, Filipe Inácio P13 Antibiotic allergy in children: room for improvement Annabelle Arnold, Natasha Bear, Kristina Rueter, Grace Gong, Michael O’Sullivan, Saravanan Muthusamy, Valerie Noble, Michaela Lucas P14 Drug hypersensitivity reactions in children and results of diagnostic evaluation Neringa Buterleviciute, Odilija Rudzeviciene P15 Nonimmediate cutaneous drug reactions in children: are skin tests required? Ana Sofia Moreira, Carmo Abreu, Eva Gomes P16 Pediatric patients with a history of penicillin allergy and a positive penicillin skin test may not be at an increased risk for multiple drug allergies Sara May, Thanai Pongdee, Miguel Park P17 Proved hypersensitivity to drugs according data of Vilnius University Hospital Santariskiu Klinikos Linas Griguola, Arturas Vinikovas, Simona Kašinskaite, Violeta Kvedariene P18 Self-reported prevalence of drug hypersensitivity reactions among students in Celal Bayar University, Turkey Ayse Aktas, Suheyla Rahman, Huseyin Elbi, Beyhan Cengiz Ozyurt P19 Severe drug hypersensitivity reactions in pediatric age Ozlem Cavkaytar, Betul Karaatmaca, Pinar Gur Cetinkaya, Saliha Esenboga, Umit M. Sahiner, Bulent E. Sekerel, Ozge Soyer Poster Walk 3: Desensitisation (P20–P28) P20 A protocol for desensitisation to valaciclovir Celia Zubrinich, Bianca Tong, Mittal Patel, Michelle Giles, Robyn O’Hehir, Robert Puy P21 A rare case of desensitization to modafinil Josefina Cernadas, Luís Amaral, Fabrícia Carolino P22 A sixteen-day desensitization protocol in delayed type hypersensitivity reactions to oral drugs Semra Demir, Asli Gelincik, Muge Olgac, Raif Caskun, Derya Unal, Bahauddin Colakoglu, Suna Buyukozturk P23 Desensitization to intravenous etoposide using a 12 and a 13-step protocol. Two cases report Olga Vega Matute, Amalia Bernad, Gabriel Gastaminza, Roselle Madamba, Carlos Lacasa, M. J. Goikoetxea, Carmen D’Amelio, Jose Rifón, Nicolas Martínez, Marta Ferrer P24 Drug desensitisation in oncology: the experience of an immunoallergology department for 5 years Carmelita Ribeiro, Emília Faria, Cristina Frutuoso, Anabela Barros, Rosário Lebre, Alice Pego, Ana Todo Bom P25 Filgrastim anaphylaxis: a successful desensitization protocol Luis Amaral, Josefina Cernadas P26 Galsulfase hypersensitivity and desensitization of a mucopolysaccharidosis VI patient Luis Felipe Ensina, Carolina Aranda, Ines Camelo Nunes, Ana Maria Martins, Dirceu Solé P27 Rapid drug desensitization with biologicals: one-center experience with four biologicals Sevim Bavbek, Resat Kendirlinan, Pamir Çerçi, Seda Tutluer, Sadan Soyyigit, Zeynep Çelebi Sözener, Ömür Aydin, Reyhan Gümüsburun P28 Successful desensitization to a high dose of methotrexate in a delayed type hypersensitivity reaction Josefina Cernadas, Leonor Carneiro-Leão, Fabrícia Carolino, Marta Almeida Poster Walk 4: SJS (P29–P38) P29 Assessment of impact of infection on drug-induced severe cutaneous adverse reactions and rhabdomyolysis using the Japanese adverse drug event report database Kimie Sai, Takuya Imatoh, Ryosuke Nakamura, Chisato Fukazawa, Yasushi Hinomura, Yoshiro Saito P30 Characterization of erythema multiforme and severe cutaneous adverse reactions hospitalizations Bernardo Sousa-Pinto, Cláudia Correia, Lídia Gomes, Sara Gil-Mata, Luís Araújo, Luís Delgado P31 Effects of infection on incidence/severity of SJS/TEN and myopathy in Japanese cases analyzed by voluntary case reports Ryosuke Nakamura, Kimie Sai, Takuya Imatoh, Yoshimi Okamoto-Uchida, Koji Kajinami, Kayoko Matsunaga, Michiko Aihara, Yoshiro Saito P32 Efficacy of tumor necrosis factor—a antagonists in Stevens–Johnson syndrome and toxic epidermal necrolysis: a randomized controlled trial and immunosuppressive effects evaluation Chuang-Wei Wang, Shih-Chi Su, Shuen-Iu Hung, Hsin-Chun Ho, Chih-Hsun Yang, Wen-Hung Chung P33 Evolution of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe: analysis of 10 years RegiSCAR-Study Maren Paulmann, Ariane Dunant, Maja Mockenhaupt, Peggy Sekula, Martin Schumacher, Sylvia Kardaun, Luigi Naldi, Teresa Bellón, Daniel Creamer, Cynthia Haddad, Bruno Sassolas, Bénédicte Lebrun-Vignes, Laurence Valeyrie-Allanore, Jean-Claude Roujeau P34 Long-term sequelae in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis: a 5-year analysis Maren Paulmann, Carmen Kremmler, Peggy Sekula, Laurence Valeyrie-Allanore, Luigi Naldi, Sylvia Kardaun, Maja Mockenhaupt P35 Major emotional complications and decreased health related quality of life among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis Roni P. Dodiuk-Gad, Cristina Olteanu, Anthony Feinstein, Rena Hashimoto, Raed Alhusayen, Sonia Whyte-Croasdaile, Yaron Finkelstein, Marjorie Burnett, Shachar Sade, Robert Cartotto, Marc Jeschke, Neil H. Shear P36 Retrospective analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients: treatment and outcome Naoko Takamura, Yumiko Yamane, Setsuko Matsukura, Kazuko Nakamura, Yuko Watanabe, Yukie Yamaguchi, Takeshi Kambara, Zenro Ikezawa, Michiko Aihara P37 Severe physical complications among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis Roni P. Dodiuk-Gad, Cristina Olteanu, Rena Hashimoto, Hall Chew, Raed Alhusayen, Sonia Whyte-Croasdaile, Yaron Finkelstein, Marjorie Burnett, Shachar Sade, Robert Cartotto, Marc Jeschke, Neil H. Shear P38 Stevens–Johnson syndrome/toxic epidermal necrolysis combined with haemophagocytic lymphohistiocytosis: a case report Brittany Knezevic, Una Nic Ionmhain, Allison Barraclough, Michaela Lucas, Matthew Anstey Poster Walk 5: Other organs/unexpected immune reactions (P39–P47) P39 A case report of patient with anti-tuberculosis drug-related severe liver failure Toru Usui, Xiaoli Meng, John Farrell, Paul Whitaker, John Watson, Neil French, Kevin Park, Dean Naisbitt P40 Acute interstitial nephritis induced by ibuprofen Ana Castro Neves, Susana Cadinha, Ana Moreira, J. P. Moreira Da Silva P41 Cetuximab induced acneiform rash—two case reports Daniela Ledic Drvar, Sandra Jerkovic Gulin, Suzana Ljubojevic Hadzavdic, Romana Ceovic P42 Enteropathy associated with losartan Ana Montoro De Francisco, Talía De Vicente Jiménez, Amelia García Luque, Natalia Rosado David, José Mª Mateos Galván P43 Granuloma annulare after therapy with canakinumab Razvigor Darlenski P44 Hypersensitivity eosinophilic myocarditis or acute coronary syndrome? Case report Dario Gulin, Jozica Sikic, Jasna Cerkez Habek, Sandra Jerkovic Gulin, Edvard Galic P45 Piperacillin-induced immune haemolytic anaemia: a severe and frequent complication of antibiotic treatment in patients with cystic fibrosis Philip Specht, Doris Staab, Beate Mayer, Jobst Roehmel P46 Progesterone triggered pemphigus foliaceus: case report Sandra Jerkovic Gulin, Caius Solovan, Anca Chiriac P47 Ramipril: triggered generalized pustular psoriasis Paola Djurinec, Kresimir Kostovic, Mirna Bradamante, Sandra Jerkovic Gulin, Romana Ceovic Poster Walk 6: NSAIDs (P48–P56) P48 Aspirin desensitization in cardiovascular disease—Portuguese experience Jose Pedro Almeida, Joana Caiado, Elisa Pedro, Pedro Canas Da Silva, Manuel Pereira Barbosa P49 Asthma and/or rhinitis to NSAIDs with good tolerance to ASA Gador Bogas, Natalia Blanca-López, Diana Pérez-Alzate, Inmaculada Doña, José Augusto Agúndez, Elena García-Martín, José Antonio Cornejo-García, Cristobalina Mayorga, María José Torres, Gabriela Canto, Miguel Blanca P50 Clinical characteristics of 196 patients with non-steroidal anti-inflammatory drug (NSAIDs) hypersensitivity Sengül Aksakal, Aytül Zerrin Sin, Zeynep Peker Koç, Fatma Düsünür Günsen, Ömür Ardeniz, Emine Nihal Mete Gökmen, Okan Gülbahar, Ali Kokuludag P51 Development of immediate hypersensitivity to several NSAIDs maintaining good tolerance to ASA Natalia Pérez-Sánchez, Natalia Blanca-López, Diana Pérez-Alzate, Gador Bogas, Inmaculada Doña, María Salas, María José Torres, Miguel Blanca, Gabriela Canto P52 Diagnosis of hypersensitivity reactions to paracetamol in a large series of cases Inmaculada Doña, Maria Salas, Francisca Gomez, Natalia Blanca-Lopez, Diana Perez-Alzate, Gador Bogas, Esther Barrionuevo, Maria Jose Torres, Inmaculada Andreu, Miguel Ángel Miranda, Gabriela Canto, Miguel Blanca P53 Hypersensitivity to paracetamol according to the new classification of hypersensitivity to NSAIDs Gabija Didžiokaite, Olesia Gaidej, Simona Kašinskaite, Violeta Kvedariene P54 Ibuprofen and other aryl propionic derivates can induce immediate selective hypersensitivity responses Diana Perez-Alzate, Natalia Blanca-López, Maria Isabel Garcimartin, Inmaculada Doña, Maria Luisa Somoza, Cristobalina Mayorga, Maria Jose Torres, Gador Bojas, Jose Antonio Cornejo-Garcia, Maria Gabriela Canto, Miguel Blanca P55 Subjects developing immediate responses to several NSAIDs can be selective with good tolerance to ASA Natalia Blanca-Lopez, Diana Pérez-Alzate, Francisco Javier Ruano Perez, Inmaculada Doña, Maria Luisa Somoza, Inmaculada Andreu, Miguel Angel Miranda, Cristobalina Mayorga, Maria Jose Torres, Jose Antonio Cornejo-Garcia, Miguel Blanca, Maria Gabriela Canto P56 Utility of low-dose oral aspirin challenges for diagnosis of aspirin exacerbated respiratory disease Elina Jerschow, Teresa Pelletier, Zhen Ren, Golda Hudes, Marek Sanak, Esperanza Morales, Victor Schuster, Simon D. Spivack, David Rosenstreich Poster Walk 7: NSAID 2 (P57–P65) P57 Alternate regulation of cyclooxygenase-2 (COX-2) MRNA expression may predispose patients to aspirin-induced exacerbations Renato Erzen, Mira Silar, Nissera Bajrovic, Matija Rijavec, Mihaela Zidarn, Peter Korosec P58 Anaphylaxis to diclofenac: what about the underlying mechanism? Leonor Carneiro-Leão, Fabrícia Carolino, Luís Amaral, Carmen Botelho, Eunice Dias-Castro, Josefina Cernadas P59 COX-2 inhibitors: are they always a safe alternative in hypersensitivity to nonsteroidal anti-inflammatory drugs? Luis Amaral, Fabricia Carolino, Eunice Castro, Josefina Cernadas P60 Management of patients with history of NSAIDs reactions prior to coronary angioplasty Mona Al-Ahmad, Tito Rodriguez P61 Oral drug challenge with non-steroidal anti-inflammatory drug under spirometric control: clinical series of 110 patients João Pedro Azevedo, Emília Faria, Beatriz Tavares, Frederico Regateiro, Ana Todo-Bom P62 Prevalence and incidence of analgesic hypersensitivity reactions in Colombia Pablo Andrés Miranda, Bautista De La Cruz Hoyos P63 Recent endoscopic sinus surgery lessens reactions during aspirin challenge in patients with aspirin exacerbated respiratory disease Teresa Pelletier, Waleed Abuzeid, Nadeem Akbar, Marc Gibber, Marvin Fried, Weiguo Han, Taha Keskin, Robert Tamayev, Golda Hudes, Simon D. Spivack, David Rosenstreich, Elina Jerschow P64 Safe use of imidazole salycilate in a case of multiple NSAIDs induced urticaria-angioedema Elisa Boni, Marina Russello, Marina Mauro P65 Selective hypersensitivity reactions to ibuprofen—seven years experience Marta Ferreira Neto Poster Walk 8: Epidemiological methods (P66–P72) P66 Allopurinol hypersensitivity: a 7-year review Lise Brosseron, Daniela Malheiro, Susana Cadinha, Patrícia Barreira, J. P. Moreira Da Silva P67 Antibiotic allergy labelling is associated with increased hospital readmission rates in Australia Brittany Knezevic, Dustin Sprigg, Michelle Trevenen, Jason Seet, Jason Trubiano, William Smith, Yogesh Jeelall, Sandra Vale, Richard Loh, Andrew Mclean-Tooke, Michaela Lucas P68 Experts’ opinions on severe cutaneous adverse drug reactions-report of a survey from the 9th international congress on cutaneous adverse drug reactions 2015 Roni P. Dodiuk-Gad, Cristina Olteanu, Wen-Hung Chung, Neil H. Shear P69 HLA-A*31-positive AGEP with carbamazepine use and other severe cutaneous adverse drug reactions (SCARs) detected by electronic medical records screening Sabine Müller, Ursula Amstutz, Lukas Jörg, Nikhil Yawalkar, Stephan Krähenbühl P70 Patients with suspected drug allergy: a specific psychological profile? Eunice Dias-Castro, Ana Leblanc, Laura Ribeiro, Josefina R. Cernadas P71 Use of an electronic device and a computerized mathematic algorithm to detect the allergic drug reactions through the analysis of heart rate variability Arantza Vega, Raquel Gutierrez Rivas, Ana Alonso, Juan Maria Beitia, Belén Mateo, Remedios Cárdenas, Juan Jesus Garcia-Dominguez P72 Variation in ERAP influences risk for HLA-B*57:01 positive abacavir hypersensitivity Rebecca Pavlos, Kaija Strautins, Ian James, Simon Mallal, Alec Redwood, Elizabeth Phillips Poster Walk 9: DRESS/AGEP (P73–P81) P73 A clinical case of DRESS syndrome in a child after administration of amoxicillin-clavulanic acid Rita Aguiar, Anabela Lopes, Ana Neves, Maria Do Céu Machado, M. A. Pereira-Barbosa P74 Acute generalized exanthematous pustulosis (AGEP) induced by mesalazine, reliable and oftenly used drug to treat inflammatory bowel disease Ceyda Tunakan Dalgiç, Emine Nihal Mete Gökmen, Fatma Düsünür Günsen, Gökten Bulut, Fatma Ömür Ardeniz, Okan Gülbahar, Ali Kokuludag, Aytül Zerrin Sin P75 Changes of blood plasmacytoid dendritic cells, myeloid dendritic cells, and basophils during the acute stage of drug reaction with eosinophilia and systemic symptoms (DRESS) and other drug eruptions Shao-Hsuan Hsu, Yung-Tsu Cho, Che-Wen Yang, Kai-Lung Chen, Chia-Yu Chu P76 Characterization of isoniazid/rifampicin-specific t-cell responses in patients with DRESS syndrome Young-Min Ye, Gyu-Young Hur, Hae-Sim Park, Seung-Hyun Kim P77 DRESS syndrome secondary to sulfasalazine with delayed TEN: a case presentation Syed Ali, Michaela Lucas, Peter N. Hollingsworth, Andrew P. C. Mclean-Tooke P78 Drug rash with eosinophilia and systemic symptoms (DRESS) features according to the culprit drug Zohra Chadly, Nadia Ben Fredj, Karim Aouam, Haifa Ben Romdhane, Naceur A. Boughattas, Amel Chaabane P79 Drug reaction with eosinophilia and systemic symptoms induced by allopurinol: not always easy to diagnose Marina Lluncor Salazar, Beatriz Pola, Ana Fiandor, Teresa Bellón, Elena Ramírez, Javier Domínguez Ortega, Santiago Quirce, Rosario Cabañas P80 Drug reaction with eosinophilia and systemic symptoms syndrome induced by two drugs simultaneously: a case report Krasimira Baynova, Marina Labella, Manuel Prados P81 The drug reaction with eosinophilia and systemic symptoms (DRESS) induced by the second-line antituberculosis drugs and Epstein–Barr virus infection Agne Ramonaite, Ieva Bajoriuniene, Brigita Sitkauskiene, Raimundas Sakalauskas Poster Walk 10: Miscellaneous drug hypersensitivity (P82–P91) P82 A case of cycloserine-induced lichenoid drug eruption confirmed with a lymphocatye transformation test Jae-Woo Kwon, Shinyoung Park P83 Allergic reaction to topical eye drops: 5 years’ retrospective study in a drug allergy unit Diana Silva, Leonor Carneiro Leão, Fabricia Carolino, Eunice Castro, Josefina Cernadas P84 Allergy to heparins Diana Perez-Alzate, Natalia Blanca-López, Maria Luisa Somoza Alvarez, Maria Garcimartin, Maria Vazquez De La Torre, Francisco Javier Ruano Pérez, Elisa Haroun, Gabriela Canto Diez P85 Allopurinol-induced adverse drug reactions Katinka Ónodi-Nagy, Ágnes Kinyó, Lajos Kemény, Zsuzsanna Bata-Csörgo P86 Analysis of a population with immediate hypersensitivity to corticosteroids: an 11 year review Joana Sofia Pita, Emília Faria, Rosa Anita Fernandes, Ana Moura, Nuno Sousa, Carmelita Ribeiro, Carlos Loureiro, Ana Todo Bom P87 Anaphylaxis against mivacurium in a 12-months old boy at first-time exposure Wolfgang Pfützner P88 Antihistamine-exacerbated chronic spontaneous urticaria: a paradox? Nadine Marrouche, Clive Grattan P89 Anti-osteoporotic agents-induced cutaneous adverse drug reactions in Asians Yu-En Chen, Chun-Bing Chen, Wen-Hung Chung, Yu-Ping Hsiao, Chia-Yu Chu P90 Diagnosis of allergic reactions to eye drops Maria Vazquez De La Torre, Natalia Blanca-Lopez, Diana Perez-Alzate, Maria Isabel Garcimartin, Francisco Javier Ruano, Maria Luisa Somoza, Elisa Haroun, Gabriela Canto P91 Diagnostic approach in suspected hypersensitivity reactions to corticosteroids Fabrícia Carolino, Eunice Dias De Castro, Josefina R. Cernadas
- Published
- 2016
43. Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury
- Author
-
Carr, Daniel F., primary, Ayehunie, Seyoum, additional, Davies, Andrea, additional, Duckworth, Carrie A., additional, French, Stephanie, additional, Hall, Neil, additional, Hussain, Syed, additional, Mellor, Howard R., additional, Norris, Alan, additional, Park, B. Kevin, additional, Penrose, Alexander, additional, Pritchard, D. Mark, additional, Probert, Chris S., additional, Ramaiah, Shashi, additional, Sadler, Claire, additional, Schmitt, Michael, additional, Shaw, Alison, additional, Sidaway, James E., additional, Vries, Robert G., additional, Wagoner, Matthew, additional, and Pirmohamed, Munir, additional
- Published
- 2017
- Full Text
- View/download PDF
44. Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population
- Author
-
Carr, Daniel F., primary, Bourgeois, Stephane, additional, Chaponda, Mas, additional, Takeshita, Louise Y., additional, Morris, Andrew P., additional, Castro, Elena M. Cornejo, additional, Alfirevic, Ana, additional, Jones, Andrew R., additional, Rigden, Daniel J., additional, Haldenby, Sam, additional, Khoo, Saye, additional, Lalloo, David G., additional, Heyderman, Robert S., additional, Dandara, Collet, additional, Kampira, Elizabeth, additional, van Oosterhout, Joep J., additional, Ssali, Francis, additional, Munderi, Paula, additional, Novelli, Giuseppe, additional, Borgiani, Paola, additional, Nelson, Matthew R., additional, Holden, Arthur, additional, Deloukas, Panos, additional, and Pirmohamed, Munir, additional
- Published
- 2017
- Full Text
- View/download PDF
45. CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations
- Author
-
Heyderman, Robert, Lalloo, David, Carr, Daniel F., Chaponda, Mas, Cornejo Castro, Elena M., Jorgensen, Andrea L., Khoo, Saye, Van Oosterhout, Joep J., Dandara, Collet, Kampira, Elizabeth, Ssali, Francis, Munderi, Paula, and Pirmohamed, Munir
- Subjects
qu_58.5 ,wa_395 ,wc_503 ,qv00056 ,qv_38 - Abstract
BACKGROUND: \ud \ud Nevirapine, an NNRTI used in HIV treatment, can cause hypersensitivity reactions in 6%-10% of patients. In the most serious cases (1.3%) this can manifest as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).\ud \ud METHODS: \ud \ud DNA samples were obtained and analysed from a total of 209 adult patients with nevirapine hypersensitivity (57 from a prospective cohort and 152 routine clinic patients) and compared with 463 control patients on nevirapine without any hypersensitivity. The case group included 70 patients with SJS/TEN. All individuals were genotyped for two SNPs in the CYP2B6 gene [c.516G>T (CYP2B6*9) and c.983T>C (CYP2B6*18)] using the TaqMan real-time genotyping platform. The replication cohort comprised 29 controls and 55 nevirapine hypersensitive patients, including 8 SJS/TEN cases.\ud \ud RESULTS: \ud \ud An association between the CYP2B6 c.983T>C polymorphism and nevirapine-induced SJS/TEN was observed. In the SJS/TEN group, 30% of individuals possessed at least one c.983T>C versus 16% in the tolerant group [P = 0.006; OR (95% CI) 2.24 (1.27-3.94)]. This association was not significant in the replication cohort [P = 0.075; OR (95% CI) 4.33 (0.80-23.57)]. Combined analysis resulted in an OR of 2.52 (95% CI 1.48-4.20; P = 0.0005) for the association of c.983T>C with SJS/TEN. No association was observed for c.983T>C with other hypersensitivity phenotypes and for CYP2B6 c.516G>T with any hypersensitivity phenotypes.\ud \ud CONCLUSIONS: \ud \ud Our data show an association between the c.983T>C polymorphism and nevirapine-induced SJS/TEN. CYP2B6 c.983T>C has a frequency of 5%-10% in a variety of African populations, but is not observed in Caucasians, thus representing an ethnic-specific predisposing factor.
- Published
- 2014
46. Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment
- Author
-
van Staa, Tjeerd P, Carr, Daniel F, O'Meara, Helen, McCann, Gerry, Pirmohamed, Munir, Sub Pharmacoepidemiology, and Pharmacoepidemiology and Clinical Pharmacology
- Abstract
AIM: The aim was to evaluate clinical risk factors associated with myotoxicity in statin users. METHODS: This was a cohort study of patients prescribed a statin in UK primary care practices contributing to the Clinical Practice Research Datalink. Outcomes of interest were creatine phosphokinase (CPK) concentrations and clinical records of rhabdomyolysis. RESULTS: The cohort comprised 641,703 statin users. Simvastatin was most frequently prescribed (66.3%), followed by atorvastatin (24.4%). CPK was measured in 127,209 patients: 81.4% within normal range and 0.7% above four times ULN CPK compared with normal CPK (OR 1.28, 95% CI 1.01, 1.60). Rosuvastatin users had higher risk of >four times ULN CPK (OR 1.62, 95% CI 1.22, 2.15) as did patients with larger daily doses of other statin types. A recent clinical record of myalgia was associated with an increased OR of >four times ULN CPK (OR 1.73, 95% CI 1.37, 2.18). In patients who were rechallenged to statins and had repeat CPK measurements after >four times ULN CPK abnormalities, 54.8% of the repeat CPK values were within normal range, 32.1% between one to three times and 13.0% >four times ULN. CONCLUSIONS: The frequencies of substantive CPK increases and rhabdomyolysis during statin treatment were low, with highest risks seen in those on large daily doses or interacting drugs and on rosuvastatin. CPK measurements appeared to have been done in a haphazard manner and better guidance is needed.
- Published
- 2014
47. Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research Datalink
- Author
-
O'Meara, Helen, Carr, Daniel F, Evely, Jane, Hobbs, Mark, McCann, Gerard, van Staa, Tjeerd, Pirmohamed, Munir, Sub Pharmacoepidemiology, and Pharmacoepidemiology and Clinical Pharmacology
- Subjects
Male ,research governance ,statin ,Middle Aged ,Specimen Handling ,electronic health records ,Muscular Diseases ,Pharmacogenetics ,Feasibility Studies ,Humans ,Female ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Saliva ,myopathy ,Aged - Abstract
AIMS: Electronic healthcare records (EHRs) are increasingly used to store clinical information. A secondary benefit of EHRs is their use, in an anonymized form, for observational research. The Clinical Practice Research Datalink (CPRD) contains EHRs from primary care in the UK and, despite 1083 peer-reviewed research publications, has never been used to obtain pharmacogenetic samples. Using a statin-induced myopathy paradigm, we evaluated using the CPRD to obtain patient samples for a pharmacogenetic study targeting 250 cases and 500 controls from UK general practitioner (GP) practices. METHODS: The CPRD identified potential patients fitting specific case-definition criteria (active rhabdomyolysis or creatine phosphokinase > four times the upper limit of normal), and corresponding GP practices were asked to invite patient participation. Consenting patients were requested to provide either saliva or blood samples and to complete an ethnicity questionnaire. Control subjects were recruited from the same GP practice (saliva) or a small number of practices (blood). Samples were forwarded for DNA extraction. RESULTS: Thirty-six months of recruitment yielded DNA samples from 149 statin-induced myopathy cases and 587 tolerant controls. Data show that contacting patients through their GP is a reliable method for obtaining samples without compromising anonymity. Saliva collection directly from patients was considerably less effective than blood sampling. After 10 months of recruitment, saliva sampling was suspended in favour of blood sampling. CONCLUSIONS: We demonstrate the potential of EHRs for identifying accurately phenotyped cases and controls for pharmacogenetic studies. Recruitment was successful only because of the willingness of GP practices to participate and the existence of strong doctor-patient relationships. The present study provides a model that can be implemented in future genetic analyses using EHRs.
- Published
- 2014
48. Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis
- Author
-
Nightingale, Sam, primary, Chau, Tran Thi Hong, additional, Fisher, Martin, additional, Nelson, Mark, additional, Winston, Alan, additional, Else, Laura, additional, Carr, Daniel F., additional, Taylor, Steven, additional, Ustianowski, Andrew, additional, Back, David, additional, Pirmohamed, Munir, additional, Solomon, Tom, additional, Farrar, Jeremy, additional, Törok, M. Estée, additional, and Khoo, Saye, additional
- Published
- 2016
- Full Text
- View/download PDF
49. Advances in the Pharmacogenomics of Adverse Drug Reactions
- Author
-
Collins, Susannah L., primary, Carr, Daniel F., additional, and Pirmohamed, Munir, additional
- Published
- 2015
- Full Text
- View/download PDF
50. Biomarkers of adverse drug reactions.
- Author
-
Carr, Daniel F. and Pirmohamed, Munir
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.